WALTHAM, Mass., 2017-11-08 15:00 CET (GLOBE NEWSWIRE) --
Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical
company focused on the development of therapies to treat central nervous system
(CNS) disorders, today announced that it will present at the Jefferies 2017
London Healthcare Conference on November 15, 2017 at 2:00 p.m. GMT (9:00 a.m.
EST).
The presentation will be web cast and accessible through the investor relations
section of the Company's web site, http://ir.minervaneurosciences.com.
About Minerva Neurosciences:
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company
focused on the development and commercialization of a portfolio of products to
treat CNS diseases. Minerva's proprietary compounds include: MIN-101, in
clinical development for schizophrenia; seltorexant (MIN-202 or JNJ-42847922),
in clinical development for insomnia and major depressive disorder (MDD);
MIN-117, in clinical development for MDD; and MIN-301, in pre-clinical
development for Parkinson's disease. Minerva's common stock is listed on the
NASDAQ Global Market under the symbol "NERV." For more information, please
visit www.minervaneurosciences.com.
Contact:
William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376© 2017 GlobeNewswire
